Drug Discovery for Ion Channels XX

Friday, February 14, 8:00 AM - 5:00 PM
San Diego Convention Center

Pre-Registration is closed.
Registration will be accepted on-site.

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. The advent of higher throughput automated electrophysiology systems has begun to change the face of ion channel drug discovery. Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques. For this year, we propose to continue the “Satellite Meeting” tradition at the Biophysical Society Annual Meeting to review the advances in automated electrophysiology and other emerging technologies and their impact on ion channel drug discovery. This year’s meeting will highlight presentations from users of automated electrophysiology instrumentation as well as other speakers in the field of ion channel drug discovery, including several academic speakers. 

 8:00 AM - 8:45 AM

Registration and Coffee, Light Breakfast 

 8:45 AM - 9:00 AM

Thais Johansen, Sophion Bioscience
Welcome and Opening Remarks
  Session I

 9:00 AM - 9:30 AM

Yan Xu, University of Pittsburgh
Nonpsychoactive Alternatives to Cannabis for Treating Pain: Discovering Novel Glycine Receptor Modulators by Automated Electrophysiology

 9:30 AM - 10:00 AM

Andre Ghetti, Anabios Corporation
Sodium Channel Blockers Inhibiting Human Sensory Neurons in Diverse Pathological States

 10:00 AM - 10:30 AM

Rocio Finol-Urdaneta, University of Wollongong
Update on IHMRI's High Throughput E-Phys Core

 10:30 AM - 11:00 AM Coffee Break
  Session II
 11:00 AM - 11:30 AM Jean-Francois Roland, Axxam
Identification of Novel Kv7.2/Kv7.3 PAMs Using Advanced High-Throughput Screening Tools 
 11:30 AM - 12:00 PM         Anton Delwig, SiteOne Therapeutics
Electrophysiological Evaluation of Novel Small-Molecule Nav1.7-Selective State-Independent Pore Blockers
 12:00 PM - 12:30 PM Matthias Gossmann, Innovitro
Examination of hiPSC-Cardiomyocyte Monolayers in 2.5D – A New Approach to Unite Physiological Relevance and Throughput
 12:30 PM - 1:30 PM Lunch
  Session III
 1:30 PM - 2:00 PM Stephen Jenkinson, Pfizer
The Use of High Throughput Multi Ion Channel Profiling and In Silico Modelling in Assessing Arrhythmia Risk - One Pharma’s Experience and Perspective
 2:00 PM – 2:30 PM David Dalrymple, SB Drug Discovery
High Throughput Screening of NMDA Receptors
 2:30 PM - 3:00 PM David Wei, Eurofins
Study Ligand Gated Ion Channels with Microfluidic Based High-Throughput, Automated Electrophysiology Platform
 3:00 PM - 3:30 PM Coffee Break
  Session IV
 3:30 PM – 4:00 PM Marc Rogers, Metrion Biosciences
Screening Toxins as Ion Channel Therapeutics on Automated Patch Clamp Systems: Kv1.3 Case Study
 4:00 PM - 4:45 PM Nieng Yan, Princeton
Challenges for the Structural Biology of Voltage-Gated Ion Channels
 4:45 PM Thomas Binzer, Sophion Bioscience
Closing Remarks

Sponsored by: